07:45 AM EDT, 04/24/2024 (MT Newswires) -- Biogen (BIIB) reported Q1 adjusted earnings Wednesday of $3.67 per diluted share, compared with $3.40 a year earlier.

Analysts polled by Capital IQ expected $3.46.

Revenue for the quarter ended March 31 was $2.29 billion, compared with $2.46 billion a year earlier.

Analysts surveyed by Capital IQ expected $2.32 billion.

For full-year 2024, the biotech company reaffirmed its guidance for adjusted earnings to be in a range of $15 to $16 per share. Analysts polled by Capital IQ expect $15.48.

Shares of Biogen were up 4% in recent Wednesday premarket activity.

Price: 201.30, Change: +8.12, Percent Change: +4.20